Cargando…
Building on success: key takeaways from the 5-year update of the KEYNOTE-407 study
Autores principales: | Gómez-Randulfe, Igor, Califano, Raffaele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483088/ https://www.ncbi.nlm.nih.gov/pubmed/37691870 http://dx.doi.org/10.21037/tlcr-23-290 |
Ejemplares similares
-
KEYNOTE-407: new hope for the treatment of lung squamous cell carcinoma
por: Zhao, Xinmin, et al.
Publicado: (2020) -
Keynote 407: the combination of pembrolizumab and chemotherapy cracks the shell of squamous cell lung cancer
por: Viteri, Santiago, et al.
Publicado: (2020) -
KEYNOTE-407: changing the way we treat stage IV squamous non-small cell lung cancer
por: Pacheco, Jose M.
Publicado: (2020) -
KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer
por: Chen, Hao, et al.
Publicado: (2023) -
Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
por: Novello, Silvia, et al.
Publicado: (2023)